← FDA DRUG APPROVALS

FDA ANDA · ANDA077672

STAVUDINE

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA077672
TYPE
ANDA
ORIGINAL APPROVAL
2008-12-29
LATEST ACTION
2020-02-10
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

STAVUDINEDiscontinued
STAVUDINE 20MG · CAPSULE · ORAL
STAVUDINEDiscontinued
STAVUDINE 40MG · CAPSULE · ORAL
STAVUDINEDiscontinued
STAVUDINE 15MG · CAPSULE · ORAL
STAVUDINEDiscontinued
STAVUDINE 30MG · CAPSULE · ORAL

Approval history

2020-02-10Labeling · Supplement 9 · standardAP
2020-02-10Labeling · Supplement 10 · standardAP
2012-09-17Labeling · Supplement 7 · standardAP
2012-03-30Labeling · Supplement 6AP
2011-07-22Labeling · Supplement 4AP
2009-09-29Labeling · Supplement 3AP
2009-03-16Labeling · Supplement 2AP
2008-12-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →